Table of Contents
ISRN Pain
Volume 2013 (2013), Article ID 245346, 16 pages
http://dx.doi.org/10.1155/2013/245346
Review Article

Tramadol Extended-Release for the Management of Pain due to Osteoarthritis

Anesthesiology and Pain Medicine, University of L’Aquila, Viale San Salvatore, Edificio 6, Coppito, 67100 L’Aquila, Italy

Received 11 February 2013; Accepted 29 April 2013

Academic Editors: M. I. Díaz-Reval, G. Krammer, and A. Ulugol

Copyright © 2013 Chiara Angeletti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Dray and S. J. Read, “Arthritis and pain. Future targets to control osteoarthritis pain,” Arthritis Research and Therapy, vol. 9, no. 3, article 212, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. D. J. Hunter, “In the clinic. Osteoarthritis,” Annals of Internal Medicine, vol. 147, no. 3, pp. ITC8-1–ITC8-16, 2007. View at Google Scholar · View at Scopus
  3. R. L. Barkin, T. R. Lubenow, S. Bruehl, B. Husfeldt, O. Ivankovich, and S. J. Barkin, “Management of chronic pain. Part I,” Disease-a-Month, vol. 42, no. 7, pp. 389–454, 1996. View at Google Scholar · View at Scopus
  4. U. Jakobsson and I. R. Hallberg, “Quality of life among older adults with osteoarthritis: an explorative study,” Journal of Gerontological Nursing, vol. 32, no. 8, pp. 51–60, 2006. View at Google Scholar · View at Scopus
  5. A. Gibofsky and R. L. Barkin, “Chronic pain of osteoarthritis: considerations for selecting an extended-release opioid analgesic,” The American Journal of Therapeutics, vol. 15, no. 3, pp. 241–255, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. W. Zhang, R. W. Moskowitz, G. Nuki et al., “OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines,” Osteoarthritis and Cartilage, vol. 16, no. 2, pp. 137–162, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. W. Zhang, M. Doherty, N. Arden et al., “EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT),” Annals of the Rheumatic Diseases, vol. 64, no. 5, pp. 669–681, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. “Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American college of rheumatology subcommittee on osteoarthritis guidelines,” Arthritis and Rheumatism, vol. 43, no. 9, pp. 1905–1915, 2000.
  9. H.-. Hennies, E. Friderichs, and J. Schneider, “Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids,” Arzneimittel-Forschung, vol. 38, no. 7, pp. 877–880, 1988. View at Google Scholar · View at Scopus
  10. R. B. Raffa, E. Friderichs, W. Reimann, R. P. Shank, E. E. Codd, and J. L. Vaught, “Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an “atypical” opioid analgesic,” Journal of Pharmacology and Experimental Therapeutics, vol. 260, no. 1, pp. 275–285, 1992. View at Google Scholar · View at Scopus
  11. R. B. Raffa, E. Friderichs, W. Reimann et al., “Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol,” Journal of Pharmacology and Experimental Therapeutics, vol. 267, no. 1, pp. 331–340, 1993. View at Google Scholar · View at Scopus
  12. E. E. Codd, R. P. Shank, J. J. Schupsky, and R. B. Raffa, “Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception,” Journal of Pharmacology and Experimental Therapeutics, vol. 274, no. 3, pp. 1263–1270, 1995. View at Google Scholar · View at Scopus
  13. M. A. Campanero, E. García-Quetglas, B. Sádaba, and J. R. Azanza, “Simultaneous stereoselective analysis of tramadol and its primary phase I metabolites in plasma by liquid chromatography: application to a pharmacokinetic study in humans,” Journal of Chromatography A, vol. 1031, no. 1-2, pp. 219–228, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. R. B. Raffa, “Basic pharmacology relevant to drug abuse assessment: tramadol as example,” Journal of Clinical Pharmacy and Therapeutics, vol. 33, no. 2, pp. 101–108, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. E. A. Shipton, “Tramadol—present and future,” Anaesthesia and Intensive Care, vol. 28, no. 4, pp. 363–374, 2000. View at Google Scholar · View at Scopus
  16. M. Barann, B. Urban, U. Stamer, Z. Dorner, H. Bönisch, and M. Brüss, “Effects of tramadol and O-demethyl-tramadol on human 5-HT reuptake carriers and human 5-HT3A receptors: a possible mechanism for tramadol-induced early emesis,” European Journal of Pharmacology, vol. 531, no. 1–3, pp. 54–58, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. E. Berrocoso, J. A. Micó, and L. Ugedo, “In vivo effect of tramadol on locus coeruleus neurons is mediated by α2-adrenoceptors and modulated by serotonin,” Neuropharmacology, vol. 51, no. 1, pp. 146–153, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. M. J. Garrido, M. Valle, M. A. Campanero, R. Calvo, and I. F. Trocóniz, “Modeling of the in vivo antinociceptive interaction between an opioid agonist, (+)-O-desmethyltramadol, and a monoamine reuptake inhibitor, (-)-O-desmethyltramadol, in rats,” Journal of Pharmacology and Experimental Therapeutics, vol. 295, no. 1, pp. 352–359, 2000. View at Google Scholar · View at Scopus
  19. E. Berrocoso, M. O. Rojas-Corrales, and J. A. Mico, “Differential role of 5-HT1A and 5-HT1B receptors on the antinociceptive and antidepressant effect of tramadol in mice,” Psychopharmacology, vol. 188, no. 1, pp. 111–118, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. P. Oliva, C. Aurilio, F. Massimo et al., “The antinociceptive effect of tramadol in the formalin test is mediated by the serotonergic component,” European Journal of Pharmacology, vol. 445, no. 3, pp. 179–185, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. D. R. Thomas, P. J. Atkinson, P. G. Hastie, J. C. Roberts, D. N. Middlemiss, and G. W. Price, “[3H]-SB-269970 radiolabels 5-HT7 receptors in rodent, pig and primate brain tissues,” Neuropharmacology, vol. 42, no. 1, pp. 74–81, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Meuser, C. Pietruck, A. Gabriel, G. Xie, K. Lim, and P. Pierce Palmer, “5-HT7 receptors are involved in mediating 5-HT-induced activation of rat primary afferent neurons,” Life Sciences, vol. 71, no. 19, pp. 2279–2289, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Doly, J. Fischer, M. Brisorgueil, D. Vergé, and M. Conrath, “Pre- and postsynaptic localization of the 5-HT7 receptor in rat dorsal spinal cord: Immunocytochemical evidence,” Journal of Comparative Neurology, vol. 490, no. 3, pp. 256–269, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. O. Yanarates, A. Dogrul, V. Yildirim et al., “Spinal 5-HT7 receptors play an important role in the antinociceptive and antihyperalgesic effects of tramadol and its metabolite, o-desmethyltramadol, via activation of descending serotonergic pathways,” Anesthesiology, vol. 112, no. 3, pp. 696–710, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. http://www.purduepharma.com/pi/prescription/Ryzolt.pdf.
  26. A. Dickman, “Tramadol: a review of this atypical opioid,” European Journal of Palliative Care, vol. 14, no. 5, pp. 181–185, 2007. View at Google Scholar · View at Scopus
  27. W. Leppert, “CYP2D6 in the metabolism of opioids for mild to moderate pain,” Pharmacology, vol. 87, no. 5-6, pp. 274–285, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. U. Klotz, “Tramadol—the impact of its pharmacokinetic and pharmacodynamic properties on the clinical management of pain,” Arzneimittel-Forschung, vol. 53, no. 10, pp. 681–687, 2003. View at Google Scholar · View at Scopus
  29. V. Subrahmanyam, A. B. Renwick, D. G. Walters et al., “Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes,” Drug Metabolism and Disposition, vol. 29, no. 8, pp. 1146–1155, 2001. View at Google Scholar · View at Scopus
  30. C. Hilgendorf, G. Ahlin, A. Seithel, P. Artursson, A. Ungell, and J. Karlsson, “Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines,” Drug Metabolism and Disposition, vol. 35, no. 8, pp. 1333–1340, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. H. Koepsell, K. Lips, and C. Volk, “Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications,” Pharmaceutical Research, vol. 24, no. 7, pp. 1227–1251, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. A. T. Nies, H. Koepsell, S. Winter et al., “Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver,” Hepatology, vol. 50, no. 4, pp. 1227–1240, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. PriCara, Ultram (Tramadol Hydrochloride) Tablets Prescribing Information, Raritan, Somerset, NJ, USA, 2009.
  34. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=23586.
  35. P. Lehtonen, T. Sten, O. Aitio et al., “Glucuronidation of racemic O-desmethyltramadol, the active metabolite of tramadol,” European Journal of Pharmaceutical Sciences, vol. 41, no. 3-4, pp. 523–530, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. L. Poulsen, L. Arendt-Nielsen, K. Brøsen, and S. H. Sindrup, “The hypoalgesic effect of tramadol in relation to CYP2D6,” Clinical Pharmacology and Therapeutics, vol. 60, no. 6, pp. 636–644, 1996. View at Publisher · View at Google Scholar · View at Scopus
  37. R. S. Pedersen, P. Damkier, and K. Brosen, “Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study,” Clinical Pharmacology and Therapeutics, vol. 77, no. 6, pp. 458–467, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. R. S. Pedersen, P. Damkier, and K. Brøsen, “Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers,” European Journal of Clinical Pharmacology, vol. 62, no. 7, pp. 513–521, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. U. M. Stamer, K. Lehnen, F. Höthker et al., “Impact of CYP2D6 genotype on postoperative tramadol analgesia,” Pain, vol. 105, no. 1-2, pp. 231–238, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. J. Kirchheiner, J. H. A. Keulen, S. Bauer, I. Roots, and J. Brockmöller, “Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol,” Journal of Clinical Psychopharmacology, vol. 28, no. 1, pp. 78–83, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. U. M. Stamer, F. Musshoff, M. Kobilay, B. Madea, A. Hoeft, and F. Stuber, “Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes,” Clinical Pharmacology and Therapeutics, vol. 82, no. 1, pp. 41–47, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. R. Kerb, U. Brinkmann, N. Chatskaia et al., “Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences,” Pharmacogenetics, vol. 12, no. 8, pp. 591–595, 2002. View at Publisher · View at Google Scholar · View at Scopus
  43. M. V. Tzvetkov, A. R. Saadatmand, K. Bokelmann, I. Meineke, R. Kaiser, and J. Brockmöller, “Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT 3 antagonists tropisetron and ondansetron,” Pharmacogenomics Journal, vol. 12, no. 1, pp. 22–29, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. U. M. Stamer, L. Zhang, and F. Stüber, “Personalized therapy in pain management: Where do we stand?” Pharmacogenomics, vol. 11, no. 6, pp. 843–864, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. M. V. Tzvetkov, A. R. Saadatmand, J. Lötsch, I. Tegeder, J. C. Stingl, and J. Brockmöller, “Genetically polymorphic OCT1: another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug tramadol,” Clinical Pharmacology and Therapeutics, vol. 90, no. 1, pp. 143–150, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. U. M. Stamer, F. Stüber, T. Muders, and F. Musshoff, “Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication,” Anesthesia and Analgesia, vol. 107, no. 3, pp. 926–929, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. W. D. Paar, P. Frankus, and H. J. Dengler, “The metabolism of tramadol by human liver microsomes,” Clinical Investigator, vol. 70, no. 8, pp. 708–710, 1992. View at Google Scholar · View at Scopus
  48. G. Mikus, A. A. Somogyi, F. Bochner, and Z. R. Chen, “Polymorphic metabolism of opioid narcotic drugs: possible clinical implications,” Annals of the Academy of Medicine Singapore, vol. 20, no. 1, pp. 9–12, 1991. View at Google Scholar · View at Scopus
  49. G. Vorsanger, D. Jordan, J. Xiang et al., “Effect of extended release tramadol on pain in the elderly,” in Proceedings of the 17th Annual Clinical Meeting of the American Academy of Pain Management, pp. 7–10, Orlando, Fla, USA, September 2006.
  50. J. B. Rose, J. C. Finkel, A. Arquedas-Mohs, B. P. Himelstein, M. Schreiner, and R. A. Medve, “Oral tramadol for the treatment of pain of 7–30 days' duration in children,” Anesthesia and Analgesia, vol. 96, no. 1, pp. 78–81, 2003. View at Publisher · View at Google Scholar · View at Scopus
  51. H. Viitanen and P. Annila, “Analgesic efficacy of tramadol 2 mg kg−1 for paediatric day-case adenoidectomy,” The British Journal of Anaesthesia, vol. 86, no. 4, pp. 572–575, 2001. View at Publisher · View at Google Scholar · View at Scopus
  52. B. V. S. Murthy, K. S. Pandya, P. D. Booker, A. Murray, W. Lintz, and R. Terlinden, “Pharmacokinetics of tramadol in children after IV or caudal epidural administration,” The British Journal of Anaesthesia, vol. 84, no. 3, pp. 346–349, 2000. View at Google Scholar · View at Scopus
  53. R.-. M. Houmes, M. A. Voets, A. Verkaaik, W. Erdmann, and B. Lachmann, “Efficacy and safety of tramadol versus morphine for moderate and severe postoperative pain with special regard to respiratory depression,” Anesthesia and Analgesia, vol. 74, no. 4, pp. 510–514, 1992. View at Google Scholar · View at Scopus
  54. P. Bozkurt, “Use of tramadol in children,” Paediatric Anaesthesia, vol. 15, no. 12, pp. 1041–1047, 2005. View at Publisher · View at Google Scholar · View at Scopus
  55. W. D. Paar, S. Poche, J. Gerloff, and H. J. Dengler, “Polymorphic CYP2D6 mediates O-demethylation of the opioid analgesic tramadol,” European Journal of Clinical Pharmacology, vol. 53, no. 3-4, pp. 235–239, 1997. View at Publisher · View at Google Scholar · View at Scopus
  56. A. C. G. Egberts, J. T. Borgh, and C. C. E. Brodie-Meijer, “Serotonin syndrome attributed to tramadol addition to paroxetine therapy,” International Clinical Psychopharmacology, vol. 12, no. 3, pp. 181–182, 1997. View at Publisher · View at Google Scholar · View at Scopus
  57. M. P. Davies, “Tramadol,” in Opioids in Cancer Pain, M. P. Davies, P. Glare, and J. Hardy, Eds., pp. 69–82, Oxford University Press, Oxford, UK, 2005. View at Google Scholar
  58. C. Vale, F. Oliveira, J. Assunção, C. Fontes-Ribeiro, and F. Pereira, “Co-administration of ondansetron decreases the analgesic efficacy of tramadol in humans,” Pharmacology, vol. 88, no. 3-4, pp. 182–187, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. N. I. Rauers, F. Stüber, E. Lee et al., “Antagonistic effects of ondansetron and tramadol? A randomized placebo and active drug controlled study,” Journal of Pain, vol. 11, no. 12, pp. 1274–1281, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. S. Grond and A. Sablotzki, “Clinical pharmacology of tramadol,” Clinical Pharmacokinetics, vol. 43, no. 13, pp. 879–923, 2004. View at Publisher · View at Google Scholar · View at Scopus
  61. C. Gasse, L. Derby, C. Vasilakis-Scaramozza, and H. Jick, “Incidence of first-time idiopathic seizures in users of tramadol,” Pharmacotherapy, vol. 20, no. 6, part 1, pp. 629–634, 2000. View at Google Scholar · View at Scopus
  62. ULTRAM ER, ULTRAM ER, (Tramadol HCl) Extended Release Tablets Package Insert, Biovail Corporation, Mississauga, Canada, Pri-Cara, a Unit of Ortho-McNeil, Raritan, Somerset, NJ, USA, 2006.
  63. R. L. Barkin, “Extended-release tramadol (ULTRAM ER): a pharmacotherapeutic, pharmacokinetic, and pharmacodynamic focus on effectiveness and safety in patients with chronic/persistent pain,” The American Journal of Therapeutics, vol. 15, no. 2, pp. 157–166, 2008. View at Publisher · View at Google Scholar · View at Scopus
  64. D. S. Tatro, Drug Interaction Facts, Wolters Kluwer Health, St. Louis, Mo, USA, 2007.
  65. P. C. Langley, A. D. Patkar, K. A. Boswell, C. J. Benson, and J. R. Schein, “Adverse event profile of tramadol in recent clinical studies of chronic osteoarthritis pain,” Current Medical Research and Opinion, vol. 26, no. 1, pp. 239–251, 2010. View at Publisher · View at Google Scholar · View at Scopus
  66. T. J. Gana, M. L. G. Pascual, R. R. B. Fleming et al., “Extended-release tramadol in the treatment of osteoarthritis: a multicenter, randomized, double-blind, placebo-controlled clinical trial,” Current Medical Research and Opinion, vol. 22, no. 7, pp. 1391–1401, 2006. View at Publisher · View at Google Scholar · View at Scopus
  67. R. L. Fishman, C. J. Kistler, M. T. Ellerbusch et al., “Efficacy and safety of 12 weeks of osteoarthritic pain therapy with once-daily tramadol (tramadol contramid OAD),” Journal of Opioid Management, vol. 3, no. 5, pp. 273–280, 2007. View at Google Scholar · View at Scopus
  68. G. Mongin, V. Yakusevich, A. Köpe et al., “Efficacy and safety assessment of a novel once-daily tablet formulation of tramadol: a randomised, controlled study versus twice-daily tramadol in patients with osteoarthritis of the knee,” Clinical Drug Investigation, vol. 24, no. 9, pp. 545–558, 2004. View at Publisher · View at Google Scholar · View at Scopus
  69. W. F. Kean, S. Bouchard, and E. Roderich-Gossen, “Women with pain due to osteoarthritis: the efficacy and safety of a once-daily formulation of tramadol,” Pain Medicine, vol. 10, no. 6, pp. 1001–1011, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. G. Vorsanger, J. Xiang, D. Jordan, and J. Farrell, “Post Hoc analysis of a randomized, double-blind, placebo-controlled efficacy and tolerability study of tramadol extended release for the treatment of osteoarthritis pain in geriatric patients,” Clinical Therapeutics, vol. 29, no. 11, supplement 1, pp. 2520–2535, 2007. View at Publisher · View at Google Scholar · View at Scopus
  71. R. R. Reeves and R. S. Burke, “Tramadol: basic pharmacology and emerging concepts,” Drugs of Today, vol. 44, no. 11, pp. 827–836, 2008. View at Publisher · View at Google Scholar · View at Scopus
  72. S. K. Barnung, M. Treschow, and F. M. Borgbjerg, “Respiratory depression following oral tramadol in a patient with impaired renal function,” Pain, vol. 71, no. 1, pp. 111–112, 1997. View at Publisher · View at Google Scholar · View at Scopus
  73. R. A. Sansone and L. A. Sansone, “Tramadol: seizure seroonin syndrome, and coadministered antidepressants,” Psychiatry, vol. 6, no. 4, pp. 17–21, 2009. View at Google Scholar · View at Scopus
  74. D. Shatin, J. S. Gardner, A. Stergachis, D. Blough, and D. Graham, “Impact of mailed warning to prescribers on the co-prescription of tramadol and antidepressants,” Pharmacoepidemiology and Drug Safety, vol. 14, no. 3, pp. 149–154, 2005. View at Publisher · View at Google Scholar · View at Scopus
  75. C. Lange-Asschenfeldt, H. Weigmann, C. Hiemke, and K. Mann, “Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology,” Journal of Clinical Psychopharmacology, vol. 22, no. 4, pp. 440–441, 2002. View at Publisher · View at Google Scholar · View at Scopus
  76. D. Mittino, M. Mula, and F. Monaco, “Serotonin syndrome associated with tramadol-sertraline coadministration,” Clinical Neuropharmacology, vol. 27, no. 3, pp. 150–151, 2004. View at Publisher · View at Google Scholar · View at Scopus
  77. F. Llinares-Tello, S. Escrivá-Moscardó, F. Martínez-Pastor, and P. Martínez-Mascaraque, “Possible serotoninergia syndrome associated with coadministration of paroxetine tramadol,” Medicina Clinica, vol. 128, no. 11, article 438, 2007. View at Google Scholar · View at Scopus
  78. L. E. Peacock and F. Wright, “Serotonin syndrome secondary to tramadol and citalopram,” Age and Ageing, vol. 40, no. 4, article 528, 2011. View at Publisher · View at Google Scholar · View at Scopus
  79. H. Karunatilake and N. A. Buckley, “Serotonin syndrome induced by fluvoxamine and oxycodone,” Annals of Pharmacotherapy, vol. 40, no. 1, pp. 155–157, 2006. View at Publisher · View at Google Scholar · View at Scopus
  80. D. J. Houlihan, “Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine,” Annals of Pharmacotherapy, vol. 38, no. 3, pp. 411–413, 2004. View at Publisher · View at Google Scholar · View at Scopus
  81. N. Nayyar, “Serotonin syndrome associated with sertraline, trazodone and tramadol abuse,” Indian Journal of Psychiatry, vol. 51, no. 1, article 68, 2009. View at Google Scholar · View at Scopus
  82. R. Kitson and B. Carr, “Tramadol and severe serotonin syndrome,” Anaesthesia, vol. 60, no. 9, pp. 934–935, 2005. View at Publisher · View at Google Scholar · View at Scopus
  83. N. Gnanadesigan, R. T. Espinoza, R. Smith, M. Israel, and D. B. Reuben, “Interaction of serotonergic antidepressants and opioid analgesics: is serotonin syndrome going undetected?” Journal of the American Medical Directors Association., vol. 6, no. 4, pp. 265–269, 2005. View at Google Scholar · View at Scopus
  84. D. J. Houlihan, “Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine,” Annals of Pharmacotherapy, vol. 38, no. 3, pp. 411–413, 2004. View at Publisher · View at Google Scholar · View at Scopus
  85. A. Tashakori and R. Afshari, “Tramadol overdose as a cause of serotonin syndrome: a case series,” Clinical Toxicology, vol. 48, no. 4, pp. 337–341, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. J. Takeshita and M. H. Litzinger, “Serotonin syndrome associated with tramadol,” Primary Care Companion to the Journal of Clinical Psychiatry, vol. 11, no. 5, article 273, 2009. View at Publisher · View at Google Scholar · View at Scopus
  87. T. J. Cicero, J. A. Inciardi, E. H. Adams et al., “Rates of abuse of tramadol remain unchanged with the introduction of new branded and generic products: results of an abuse monitoring system, 1994–2004,” Pharmacoepidemiology and Drug Safety, vol. 14, no. 12, pp. 851–859, 2005. View at Publisher · View at Google Scholar · View at Scopus
  88. J. A. Inciardi, T. J. Cicero, A. Muñoz et al., “The diversion of ultram, ultracet, and generic tramadol HCL,” Journal of Addictive Diseases, vol. 25, no. 2, pp. 53–58, 2006. View at Publisher · View at Google Scholar · View at Scopus
  89. G. Mongin, “Tramadol extended-release formulations in the management of pain due to osteoarthritis,” Expert Review of Neurotherapeutics, vol. 7, no. 12, pp. 1775–1784, 2007. View at Publisher · View at Google Scholar · View at Scopus
  90. D. Karhu, C. Fradette, M. A. Potgieter, M. M. Ferreira, and J. Terblanché, “Comparative pharmacokinetics of a once-daily tramadol extended-release tablet and an immediate-release reference product following single-dose and multiple-dose administration,” Journal of Clinical Pharmacology, vol. 50, no. 5, pp. 544–553, 2010. View at Publisher · View at Google Scholar · View at Scopus
  91. J. V. Pergolizzi Jr., R. Taylor Jr., and R. B. Raffa, “Extended-release formulations of tramadol in the treatment of chronic pain,” Expert Opinion on Pharmacotherapy, vol. 12, no. 11, pp. 1757–1768, 2011. View at Publisher · View at Google Scholar · View at Scopus
  92. B. P. Murthy, D. M. Skee, A. P. Danyluk, V. Brett, G. J. Vorsanger, and B. L. Moskovitz, “Pharmacokinetic model and simulations of dose conversion from immediate- to extended-release tramadol,” Current Medical Research and Opinion, vol. 23, no. 2, pp. 275–284, 2007. View at Publisher · View at Google Scholar · View at Scopus
  93. C. Hernandez-Lopez, L. Martinez-Farnos, D. Karhu, T. Perez-Campos, S. Rovira, and G. Encina, “Comparative bioavailability between two tramadol once-daily oral formulations,” Methods and Findings in Experimental and Clinical Pharmacology, vol. 28, no. 6, pp. 373–378, 2006. View at Publisher · View at Google Scholar · View at Scopus
  94. A. Wamke, B. Schug, F. Vanderbist, and H. Blume, “Significance of the biopharmaceutical properties of tramadol sustained-release formulations for chrono-pharmacologically optimized treatment of pain from various sources,” International Journal of Clinical Pharmacology and Therapeutics, vol. 47, no. 6, pp. 405–412, 2009. View at Google Scholar · View at Scopus
  95. J. C. Lai, S. Sista, and O. Eradiri, “The pharmacokinetic of novel once daily tramadol hydrochloride extended release tablets in healthy subjects,” in Proceedings of the Annual Meeting of the American Association of Pharmaceutical Scientists, abstract M1071, pp. 26–30, Salk Lake City, Utah, USA, October 2003.
  96. H. Malonne, B. Sonet, B. Streel et al., “Pharmacokinetic evaluation of a new oral sustained release dosage form of tramadol,” The British Journal of Clinical Pharmacology, vol. 57, no. 3, pp. 270–278, 2004. View at Publisher · View at Google Scholar · View at Scopus
  97. D. Karhu and S. Bouchard, “Pharmacokinetic evaluation of a novel once-a-day tramadol hydroclhoride formulation,” in Proceedings of the American College of Clinical Pharmacology (ACCP) Annual Meeting, poster 14, Rockville, USA, September 2005.
  98. CIP Tramadol ER, 2011, http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2347726f-7755-7026-426c-6f7741776179.
  99. N. Babul, R. Noveck, H. Chipman, S. H. Roth, T. Gana, and K. Albert, “Efficacy and safety of extended-release, once-daily tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis of the knee,” Journal of Pain and Symptom Management, vol. 28, no. 1, pp. 59–71, 2004. View at Publisher · View at Google Scholar · View at Scopus
  100. C. Thorne, A. D. Beaulieu, D. J. Callaghan et al., “A randomized, double-blind, crossover comparison of the efficacy and safety of oral controlled-release tramadol and placebo in patients with painful osteoarthritis,” Pain Research and Management, vol. 13, no. 2, pp. 93–102, 2008. View at Google Scholar · View at Scopus
  101. B. P. DeLemos, J. Xiang, C. Benson, T. J. Gana, M. L. G. Pascual, and R. R. B. Fleming, “Tramadol hydrochloride extended-release once-daily in the treatment of osteoarthritis of the knee and/or hip: a double-blind, randomized, dose-ranging trial,” The American Journal of Therapeutics, vol. 18, no. 3, pp. 216–226, 2011. View at Publisher · View at Google Scholar · View at Scopus
  102. S. Wilcox, G. A. Brenes, D. Levine, M. A. Sevick, S. A. Shumaker, and T. Craven, “Factors related to sleep disturbance in older adults experiencing knee pain or knee pain with radiographic evidence of knee osteoarthritis,” Journal of the American Geriatrics Society, vol. 48, no. 10, pp. 1241–1251, 2000. View at Google Scholar · View at Scopus
  103. O. G. Florete, J. Xiang, and G. J. Vorsanger, “Effects of extended-release tramadol on pain-related sleep parameters in patients with osteoarthritis,” Expert Opinion on Pharmacotherapy, vol. 9, no. 11, pp. 1817–1827, 2008. View at Publisher · View at Google Scholar · View at Scopus
  104. W. A. Katz and R. L. Barkin, “Dilemmas in chronic/persistent pain management,” The American Journal of Therapeutics, vol. 15, no. 3, pp. 256–264, 2008. View at Publisher · View at Google Scholar · View at Scopus
  105. J. Hippisley-Cox, C. Coupland, and R. Logan, “Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis,” The British Medical Journal, vol. 331, no. 7528, pp. 1310–1316, 2005. View at Publisher · View at Google Scholar · View at Scopus
  106. P. M. Kearney, C. Baigent, J. Godwin, H. Halls, J. R. Emberson, and C. Patrono, “Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials,” The British Medical Journal, vol. 332, no. 7553, pp. 1302–1308, 2006. View at Google Scholar · View at Scopus
  107. R. L. Barkin and A. Buvanendran, “Focus on the COX-1 and COX-2 agents: renal events of nonsteroidal and anti-inflammatory drugs-NSAIDs,” The American Journal of Therapeutics, vol. 11, no. 2, pp. 124–129, 2004. View at Google Scholar · View at Scopus
  108. E. M. Antman, J. S. Bennett, A. Daugherty, C. Furberg, H. Roberts, and K. A. Taubert, “Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American heart association,” Circulation, vol. 115, no. 12, pp. 1634–1642, 2007. View at Publisher · View at Google Scholar · View at Scopus
  109. A. Rostom, L. Goldkind, and L. Laine, “Nonsteroidal anti-inflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients,” Clinical Gastroenterology and Hepatology, vol. 3, no. 5, pp. 489–498, 2005. View at Publisher · View at Google Scholar · View at Scopus
  110. R. L. Barkin, M. Beckerman, S. L. Blum, F. M. Clark, E. Koh, and D. S. Wu, “Should nonsteroidal anti-inflammatory drugs (NSAIDs) be prescribed to the older adult?” Drugs and Aging, vol. 27, no. 10, pp. 775–789, 2010. View at Publisher · View at Google Scholar · View at Scopus
  111. R. L. Barkin and A. Buvanendran, “Focus on the COX-1 and COX-2 agents: renal events of nonsteroidal and anti-inflammatory drugs-NSAIDs,” The American Journal of Therapeutics, vol. 11, no. 2, pp. 124–129, 2004. View at Google Scholar · View at Scopus
  112. F. Andersohn, S. Suissa, and E. Garbe, “Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction,” Circulation, vol. 113, no. 16, pp. 1950–1957, 2006. View at Publisher · View at Google Scholar · View at Scopus
  113. B. Caldwell, S. Aldington, M. Weatherall, P. Shirtcliffe, and R. Beasley, “Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis,” Journal of the Royal Society of Medicine, vol. 99, no. 3, pp. 132–140, 2006. View at Publisher · View at Google Scholar · View at Scopus
  114. L. Manchikanti, S. Helm, B. Fellows et al., “Opioid epidemic in the United States,” Pain Physician, vol. 15, no. 3, supplement, pp. ES9–ES38, 2012. View at Google Scholar